Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Sold by Platinum Investment Management Ltd.

Platinum Investment Management Ltd. trimmed its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 13.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 370,278 shares of the company’s stock after selling 59,423 shares during the period. Platinum Investment Management Ltd.’s holdings in Centessa Pharmaceuticals were worth $6,202,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CNTA. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares in the last quarter. Atria Investments Inc boosted its position in Centessa Pharmaceuticals by 7.0% during the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock worth $274,000 after purchasing an additional 1,116 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after purchasing an additional 5,316 shares in the last quarter. Walleye Capital LLC purchased a new position in Centessa Pharmaceuticals during the third quarter worth approximately $187,000. Finally, Geode Capital Management LLC boosted its position in Centessa Pharmaceuticals by 68.7% during the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock worth $905,000 after purchasing an additional 23,058 shares in the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $16.51 on Wednesday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock’s 50-day moving average price is $16.45 and its 200 day moving average price is $16.36. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The stock has a market capitalization of $2.18 billion, a PE ratio of -10.79 and a beta of 1.54.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total transaction of $170,400.00. Following the transaction, the insider now owns 183,266 shares of the company’s stock, valued at $3,122,852.64. This represents a 5.17 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the sale, the chief executive officer now owns 520,661 shares of the company’s stock, valued at approximately $9,080,327.84. The trade was a 9.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 247,168 shares of company stock valued at $4,138,928 in the last quarter. 11.59% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $26.00.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.